TapImmune President and CEO, Peter Hoang, will be presenting at the 29th Annual Piper Jaffray Healthcare Conference.
Chairman and Strategic Advisor Glynn Wilson, Ph.D., and Senior Director of Molecular Biology & Virology Robert Florkiewicz, Ph.D., will give an oral presentation titled, “Increasing the potency of DNA-based immunotherapies using PolyStart™ peptide expression system,” at the World Vaccine & Immunotherapy Congress West Coast, held Thursday, November 30 – December 1, 2017, at the Loews Coronado Bay Resort in San Diego, CA.
Please join us for TapImmune’s third quarter 2017 corporate and clinical update today, Novmber 15th at 4:30pm ET.
TapImmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer
Triple-negative breast cancer is a difficult-to-treat condition, but one where patients may stand to benefit significantly from immunotherapies that are effective at continually fighting off disease progression long after initial cancer therapy. As a multi-peptide therapeutic vaccine, TPIV200 is designed to do just that.
Please join us for our third quarterly call update of 2017 on November 15, 2017 at 4:30pm.
Peter L. Hoang pens a personal letter to TapImmune’s shareholders.
TapImmune will be attending and presenting at the 20th Bioflorida Conference in St. Petersburg, Florida.
TapImmune Welcomes Peter L. Hoang as President and Chief Executive Officer.
Today TapImmune provides its business update for the second quarter 2017. A public conference call and live audio webcast is scheduled for today at 4:30 p.m. ET.
TapImmune, Inc. today announced that the Company will host a conference call and live audio webcast on Thursday, August 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the second quarter 2017.